Patents by Inventor Jens HUKELMANN

Jens HUKELMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12318407
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: June 3, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12290530
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: May 6, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use immunotherapy against different types of cancers
    Patent number: 12285443
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: April 29, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use immunotherapy against different types of cancers
    Patent number: 12274716
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: April 15, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12257269
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: March 25, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12246039
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2024
    Date of Patent: March 11, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240374642
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: November 14, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240374640
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: November 14, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240366669
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: November 7, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240358755
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 31, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240358757
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: October 31, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240358756
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 31, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240307447
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: September 19, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240299455
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: September 12, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240279306
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 4, 2024
    Publication date: August 22, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240269183
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 15, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240269184
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 15, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240254191
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 1, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240245723
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 23, 2024
    Publication date: July 25, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240247045
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 6, 2024
    Publication date: July 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR